Q1 EPS Estimate for Kymera Therapeutics Boosted by Analyst

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Equities researchers at HC Wainwright boosted their Q1 2026 earnings per share estimates for Kymera Therapeutics in a research report issued to clients and investors on Monday, March 2nd. HC Wainwright analyst A. Fein now forecasts that the company will earn ($0.73) per share for the quarter, up from their prior estimate of ($0.76). HC Wainwright has a “Buy” rating and a $134.00 price target on the stock. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share. HC Wainwright also issued estimates for Kymera Therapeutics’ Q2 2026 earnings at ($0.74) EPS, Q3 2026 earnings at ($0.75) EPS, Q4 2026 earnings at ($0.74) EPS, FY2026 earnings at ($2.96) EPS, FY2027 earnings at ($3.26) EPS, FY2028 earnings at ($3.35) EPS, FY2029 earnings at ($2.64) EPS and FY2030 earnings at $1.34 EPS.

KYMR has been the subject of several other research reports. BTIG Research decreased their price target on shares of Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. Morgan Stanley reaffirmed an “overweight” rating and set a $123.00 target price on shares of Kymera Therapeutics in a research report on Thursday, February 26th. Bank of America upped their target price on Kymera Therapeutics from $71.00 to $112.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Stifel Nicolaus set a $114.00 price target on Kymera Therapeutics in a research note on Monday, December 8th. Finally, Citigroup upped their price objective on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $119.50.

Kymera Therapeutics Price Performance

Kymera Therapeutics stock opened at $86.11 on Thursday. The stock has a market cap of $7.03 billion, a price-to-earnings ratio of -23.40 and a beta of 2.20. The firm has a 50-day moving average of $78.75 and a two-hundred day moving average of $66.40. Kymera Therapeutics has a 1 year low of $19.44 and a 1 year high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). The company had revenue of $2.87 million for the quarter, compared to analysts’ expectations of $14.80 million. Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The firm’s revenue for the quarter was down 60.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.88) earnings per share.

Institutional Investors Weigh In On Kymera Therapeutics

A number of large investors have recently modified their holdings of KYMR. PNC Financial Services Group Inc. increased its holdings in shares of Kymera Therapeutics by 506.6% during the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after acquiring an additional 770 shares in the last quarter. Smartleaf Asset Management LLC grew its position in Kymera Therapeutics by 382.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after purchasing an additional 424 shares during the last quarter. Larson Financial Group LLC increased its stake in Kymera Therapeutics by 81.5% during the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after purchasing an additional 349 shares in the last quarter. Osaic Holdings Inc. raised its holdings in shares of Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after buying an additional 1,083 shares during the last quarter. Finally, Bessemer Group Inc. lifted its stake in shares of Kymera Therapeutics by 652.0% during the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after buying an additional 815 shares during the period.

Insiders Place Their Bets

In other Kymera Therapeutics news, Director Bruce Booth sold 229,809 shares of the stock in a transaction dated Wednesday, December 10th. The shares were sold at an average price of $91.73, for a total transaction of $21,080,379.57. Following the completion of the sale, the director directly owned 686,477 shares of the company’s stock, valued at approximately $62,970,535.21. This represents a 25.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Jared Gollob sold 49,307 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $88.67, for a total transaction of $4,372,051.69. Following the completion of the transaction, the insider directly owned 109,992 shares in the company, valued at approximately $9,752,990.64. The trade was a 30.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 561,698 shares of company stock valued at $50,388,337 in the last three months. 16.01% of the stock is currently owned by insiders.

Trending Headlines about Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: UBS raised its price target sharply (from $90 to $128) and kept a Buy rating, citing pipeline progress; the lift represents material upside from current levels and is a primary reason for today’s upward move. UBS price target raise
• Positive Sentiment: AmericanBankingNews reports a price-target increase to $100 and notes UBS commentary that KYMR stock is expected to rise — additional analyst attention supporting buying interest. Price Target Raised to $100.00
• Positive Sentiment: Pipeline and balance-sheet strength highlighted in recent coverage: Seeking Alpha notes Kymera’s $1.6B cash position and that management is aggressively funding mid‑stage advancement of KT‑621 and KT‑579 — these program milestones (KT‑579 data in 2H26; KT‑621 Phase 2b readouts in 2027) are key longer‑term catalysts. Pipeline enters defining clinical phase
• Positive Sentiment: Broader media roundup (The Globe and Mail) flags Kymera among healthcare names receiving bullish analyst attention, reinforcing momentum from the UBS call. Analysts are bullish
• Neutral Sentiment: Market context: KYMR opened near $86.11 today, sits well above its 200‑day moving average and below its 52‑week high — technicals support further upside but imply volatility (beta ~2.2).
• Negative Sentiment: Large insider selling disclosed in multiple Form 4 filings: Director Bruce Booth sold 81,866 shares (~$7.38M at ~$90). Such a sizable director sale can be interpreted as material profit‑taking and may cap near‑term upside. Booth Form 4
• Negative Sentiment: Multiple senior execs (CFO Bruce Jacobs, COO Jeremy Chadwick, insider Jared Gollob) sold shares across March 2–4 at ~$85–$89, reducing positions by a few percent each. Repeated executive sales may raise governance/market‑sentiment concerns despite the company’s cash runway. Exec filings

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.